Announced details
Unresectable, locally advanced or locally recurrent head and neck cancer. If a new indication is approved in Japan in the future, it may become eligible for treatment in the Hainan Island Medical Special Zone.
1 patient treated on each of 19 and 20 March 2026 (2 patients in total; actual results as of the commencement of treatment)
The Company entered into a basic agreement with 中国生物科技服務控股有限公司 and Pengbo in June 2022 for the supply of Steboronin. The Company is working with SUMITOMO HEAVY INDUSTRIES,LTD. to combine its BNCT treatment system and dose calculation program with Steboronin and, in cooperation with Pengbo, develop BNCT services in the Hainan Island Medical Special Zone.
SUMITOMO HEAVY INDUSTRIES,LTD. is headquartered in Shinagawa-ku, Tokyo. 中国生物科技服務控股有限公司 is listed on the Hong Kong Stock Exchange under Stock Code: 8037. Pengbo is a subsidiary of 中国生物科技服務控股有限公司. It obtained a license to engage in medical institution-related business in the Hainan Island Medical Special Zone and established and operates the Pengbo (Hainan) BNCT Center. Other details: Not disclosed.
Boao Lecheng International Medical Tourism Pilot Zone, Hainan, China
The impact on results for the fiscal year ending March 2026 is immaterial.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Steboronine, BNCT (boron neutron capture therapy), NeuCure, NeuCure Dose Engine |
| Counterparty | 中国生物科技服務控股有限公司 (Hong Kong Stock Exchange, Stock Code: 8037), 鵬博(海南)硼中子医療科技有限公司 (Pengbo), SUMITOMO HEAVY INDUSTRIES,LTD. |
| Counterparty overview | SUMITOMO HEAVY INDUSTRIES,LTD. is headquartered in Shinagawa-ku, Tokyo. 中国生物科技服務控股有限公司 is listed on the Hong Kong Stock Exchange under Stock Code: 8037. Pengbo is a subsidiary of 中国生物科技服務控股有限公司. It obtained a license to engage in medical institution-related business in the Hainan Island Medical Special Zone and established and operates the Pengbo (Hainan) BNCT Center. Other details: Not disclosed. |
| Relationship with the Company | The Company entered into a basic agreement with 中国生物科技服務控股有限公司 and Pengbo in June 2022 for the supply of Steboronin. The Company is working with SUMITOMO HEAVY INDUSTRIES,LTD. to combine its BNCT treatment system and dose calculation program with Steboronin and, in cooperation with Pengbo, develop BNCT services in the Hainan Island Medical Special Zone. |
| Contract Date | June 2022 (basic agreement) |
| Launch date | 19 March 2026 (actual; first treatment for head and neck cancer), with treatment also administered to 1 patient on 20 March 2026. The Center opened on 7 February 2026 (actual). |
| Applicable area | Unresectable, locally advanced or locally recurrent head and neck cancer. If a new indication is approved in Japan in the future, it may become eligible for treatment in the Hainan Island Medical Special Zone. |
| Location | Boao Lecheng International Medical Tourism Pilot Zone, Hainan, China |
| Usage history | 1 patient treated on each of 19 and 20 March 2026 (2 patients in total; actual results as of the commencement of treatment) |
| Impact on Business Performance | The impact on results for the fiscal year ending March 2026 is immaterial. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Following the Center's opening, its medical team held repeated consultations with Osaka Medical and Pharmaceutical University, including case reviews, and proceeded with preparations for the first treatment. The Center was also partially damaged by flooding caused by a typhoon at the end of October 2024, and restoration work required time.